WuXi Biologics Reports Record 2025 Annual Results, Fueled by Operational Excellence and Digital-Native Innovation

WuXi Biologics Announces Record 2025 Annual Results, Fueled by Operational Excellence and Digital-Native Infrastructure WuXi Biologics has reported strong financial and operational performance for 2025, marking a year of significant…

Read MoreWuXi Biologics Reports Record 2025 Annual Results, Fueled by Operational Excellence and Digital-Native Innovation

Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Reach 100,000 Patients and Healthcare Workers in Two-Year Pilot

Pet Partners and Baxter Foundation Expand Therapy Animal Programs to Reach 100,000 Patients and Healthcare Workers in Two-Year Pilot Pet Partners and the Baxter Foundation, the charitable arm of Baxter…

Read MorePet Partners and the Baxter Foundation Expand Therapy Animal Programs to Reach 100,000 Patients and Healthcare Workers in Two-Year Pilot

Merck & Co. to Acquire Terns Pharmaceuticals, Inc., Strengthening Hematology Pipeline with TERN-701 for Chronic Myeloid Leukemia (CML)

Merck & Co., Inc. to Acquire Terns Pharmaceuticals, Inc., Strengthening Hematology Pipeline with TERN-701 for Chronic Myeloid Leukemia (CML) Merck & Co.—known as MSD outside the United States and Canada—and…

Read MoreMerck & Co. to Acquire Terns Pharmaceuticals, Inc., Strengthening Hematology Pipeline with TERN-701 for Chronic Myeloid Leukemia (CML)